LivaNova (LIVN) Net Cash Flow Growth (3y) (2019 - 2026)
LivaNova (LIVN) Net Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.91 Bn | 193.31 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.59 Bn | 124.11 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.24 Bn | 72.70 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.38 Bn | 32.44 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.96 Bn | 31.85 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.08 Bn | 22.60 Bn | 684.20 Mn | 269.22% |
| 10 | LivaNova | 4.29 Bn | 3.77 Bn | 273.67 Mn | -57.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.49% |
| Mar 31, 2026 | -193.11% |
| Dec 31, 2025 | -55.55% |
| Sep 30, 2025 | -20.06% |
| Jun 30, 2025 | -67.97% |
| Mar 31, 2025 | -66.41% |
| Dec 31, 2024 | 34.47% |
| Sep 30, 2024 | 30.05% |
| Jun 30, 2024 | -37.22% |
| Mar 31, 2024 | 215.83% |
| Dec 31, 2023 | 16.45% |
| Sep 30, 2023 | 38.52% |
| Jun 30, 2023 | -52.41% |
| Mar 31, 2023 | -60.59% |
| Dec 31, 2022 | 33.97% |
| Sep 30, 2022 | 47.62% |
| Jun 30, 2022 | -69.31% |
| Mar 31, 2022 | 291.43% |
| Dec 31, 2021 | 41.57% |
| Sep 30, 2021 | -85.98% |